Oxford Biomedica (LON:OXB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a research report issued to clients and investors on Wednesday,Digital Look reports. They presently have a GBX 1,170 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective indicates a potential upside of 103.48% from the stock’s previous close.
Several other research firms also recently issued reports on OXB. Jefferies Financial Group restated a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a report on Tuesday. Stifel Nicolaus restated a “buy” rating and set a GBX 950 price objective on shares of Oxford Biomedica in a report on Wednesday, March 11th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of GBX 604.32.
View Our Latest Research Report on Oxford Biomedica
Oxford Biomedica Stock Performance
Oxford Biomedica (LON:OXB – Get Free Report) last released its quarterly earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. As a group, sell-side analysts expect that Oxford Biomedica will post -31.0799998 EPS for the current fiscal year.
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
Featured Stories
- Five stocks we like better than Oxford Biomedica
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
